ROCKWELL MEDICAL, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
ROCKWELL MEDICAL, INC. (RMTI) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $14.84 million for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-15
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $14.84M, a 10.82% increase year-over-year.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $14.63M, a 14.14% increase year-over-year.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $13.24M, a 1.56% decline year-over-year.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $14.59M, a 7.08% increase year-over-year.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $57.30M, a 7.54% increase from fiscal 2016.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $53.28M, a 3.73% decline from fiscal 2015.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $55.35M, a 2.14% increase from fiscal 2014.
- ROCKWELL MEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $54.19M, a 3.45% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $14.84M 10-K · filed 2018-03-15 | $29.46M derived: sum of 2 quarters · filed 2018-03-15 | $42.71M derived: sum of 3 quarters · filed 2018-03-15 | $57.30M 10-K · filed 2018-03-15 |
| 2017-09-30 | $14.63M 10-K · filed 2018-03-15 | $27.87M derived: sum of 2 quarters · filed 2018-03-15 | $42.46M 10-Q · filed 2017-11-08 | $55.85M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | $13.24M 10-K · filed 2018-03-15 | $27.84M 10-Q · filed 2017-08-09 | $41.23M derived: sum of 3 quarters · filed 2018-03-15 | $54.04M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | $14.59M 10-K · filed 2018-03-15 | $27.98M derived: sum of 2 quarters · filed 2018-03-15 | $40.80M derived: sum of 3 quarters · filed 2018-03-15 | $54.25M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | $13.39M 10-K · filed 2018-03-15 | $26.20M derived: sum of 2 quarters · filed 2018-03-15 | $39.66M derived: sum of 3 quarters · filed 2018-03-15 | $53.28M 10-K · filed 2018-03-15 |
| 2016-09-30 | $12.81M 10-K · filed 2018-03-15 | $26.27M derived: sum of 2 quarters · filed 2018-03-15 | $39.89M 10-Q · filed 2017-11-08 | $54.03M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-06-30 | $13.45M 10-K · filed 2018-03-15 | $27.08M 10-Q · filed 2017-08-09 | $41.21M derived: sum of 3 quarters · filed 2018-03-15 | $55.59M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-03-31 | $13.63M 10-K · filed 2018-03-15 | $27.76M derived: sum of 2 quarters · filed 2018-03-15 | $42.14M derived: sum of 3 quarters · filed 2018-03-15 | $55.09M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-12-31 | $14.13M 10-K · filed 2017-03-15 | $28.51M derived: sum of 2 quarters · filed 2017-03-15 | $41.47M derived: sum of 3 quarters · filed 2017-03-15 | $55.35M 10-K · filed 2018-03-15 |
| 2015-09-30 | $14.38M 10-K · filed 2017-03-15 | $27.33M derived: sum of 2 quarters · filed 2017-03-15 | $41.22M 10-Q · filed 2016-11-07 | $55.67M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $12.96M 10-K · filed 2017-03-15 | $26.84M 10-Q · filed 2016-08-09 | $41.29M derived: sum of 3 quarters · filed 2017-03-15 | $55.03M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $13.88M 10-K · filed 2017-03-15 | $28.33M derived: sum of 2 quarters · filed 2017-03-15 | $42.08M derived: sum of 3 quarters · filed 2017-03-15 | $55.11M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $14.45M 10-K · filed 2016-02-29 | $28.19M derived: sum of 2 quarters · filed 2016-02-29 | $41.22M derived: sum of 3 quarters · filed 2016-02-29 | $54.19M 10-K · filed 2017-03-15 |
| 2014-09-30 | $13.74M 10-K · filed 2016-02-29 | $26.78M derived: sum of 2 quarters · filed 2016-02-29 | $39.74M 10-Q · filed 2015-11-09 | $53.71M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $13.03M 10-K · filed 2016-02-29 | $26.00M 10-Q · filed 2015-08-04 | $39.96M derived: sum of 3 quarters · filed 2016-02-29 | $53.06M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $12.96M 10-K · filed 2016-02-29 | $26.93M derived: sum of 2 quarters · filed 2016-02-29 | $40.02M derived: sum of 3 quarters · filed 2016-02-29 | $53.01M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $13.96M 10-K · filed 2015-03-03 | $27.06M derived: sum of 2 quarters · filed 2015-03-03 | $40.04M derived: sum of 3 quarters · filed 2015-03-03 | $52.38M 10-K · filed 2016-02-29 |
| 2013-09-30 | $13.09M 10-K · filed 2015-03-03 | $26.08M derived: sum of 2 quarters · filed 2015-03-03 | $38.41M 10-Q · filed 2014-11-10 | $51.41M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-06-30 | $12.98M 10-K · filed 2015-03-03 | $25.32M 10-Q · filed 2014-07-31 | $38.32M derived: sum of 3 quarters · filed 2015-03-03 | $51.01M derived: sum of 4 quarters · filed 2015-03-03 |
| 2013-03-31 | $12.34M 10-K · filed 2015-03-03 | $25.34M derived: sum of 2 quarters · filed 2015-03-03 | $38.03M derived: sum of 3 quarters · filed 2015-03-03 | $50.15M derived: sum of 4 quarters · filed 2015-03-03 |
| 2012-12-31 | $13.00M 10-K · filed 2014-03-07 | $25.69M derived: sum of 2 quarters · filed 2014-03-07 | $37.81M derived: sum of 3 quarters · filed 2014-03-07 | $49.84M 10-K · filed 2015-03-03 |
| 2012-09-30 | $12.69M 10-K · filed 2014-03-07 | $24.81M derived: sum of 2 quarters · filed 2014-03-07 | $36.84M 10-Q · filed 2013-11-05 | $48.74M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-06-30 | $12.12M 10-K · filed 2014-03-07 | $24.15M 10-Q · filed 2013-08-01 | $36.05M derived: sum of 3 quarters · filed 2014-03-07 | $48.03M derived: sum of 4 quarters · filed 2014-03-07 |
| 2012-03-31 | $12.03M 10-K · filed 2014-03-07 | $23.93M derived: sum of 2 quarters · filed 2014-03-07 | $35.90M derived: sum of 3 quarters · filed 2014-03-07 | $47.70M derived: sum of 4 quarters · filed 2014-03-07 |
| 2011-12-31 | $11.90M 10-K · filed 2013-03-18 | $23.87M derived: sum of 2 quarters · filed 2013-03-18 | $35.68M derived: sum of 3 quarters · filed 2013-03-18 | $48.97M 10-K · filed 2014-03-07 |
| 2011-09-30 | $11.98M 10-K · filed 2013-03-18 | $23.78M derived: sum of 2 quarters · filed 2013-03-18 | $37.07M 10-Q · filed 2012-11-09 | $51.39M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $11.80M 10-K · filed 2013-03-18 | $25.09M 10-Q · filed 2012-08-07 | $39.42M derived: sum of 3 quarters · filed 2013-03-18 | $54.16M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $13.29M 10-K · filed 2013-03-18 | $27.61M derived: sum of 2 quarters · filed 2013-03-18 | $42.36M derived: sum of 3 quarters · filed 2013-03-18 | $57.87M derived: sum of 4 quarters · filed 2013-03-18 |
| 2010-12-31 | $14.32M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $29.07M derived: sum of 2 quarters · filed 2013-03-18 | $44.57M derived: sum of 3 quarters · filed 2013-03-18 | $59.55M 10-K · filed 2013-03-18 |
| 2010-09-30 | $14.75M 10-Q · filed 2011-11-04 | $30.25M derived: sum of 2 quarters · filed 2011-11-04 | $45.23M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $15.51M 10-Q · filed 2011-08-05 | $30.49M 10-Q · filed 2011-08-05 | ||
| 2009-12-31 | $54.73M 10-K · filed 2012-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B |